Financials data is unavailable for this security.
Cash flow in USDView more
In 2023, cash reserves at Zyversa Therapeutics Inc fell by 2.76m. Cash Flow from Financing totalled 5.96m or -- of revenues. In addition the company used 8.72m for operations while cash used for investing totalled .
Cash flow per share | -49.37 |
---|---|
Price/Cash flow per share | -- |
Book value per share | 10.32 |
---|---|
Tangible book value per share | -12.01 |
More ▼
Balance sheet in USDView more
Current ratio | 0.0642 |
---|---|
Quick ratio | -- |
Total debt/total equity | 0.00 |
---|---|
Total debt/total capital | 0.00 |
More ▼